Prescription Drug Marketing Act

Prescription Drug Marketing Act of 1987

The Prescription Drug Marketing Act of 1987 (PDMA) is a significant piece of legislation in the United States that was enacted to ensure the safety and security of prescription drugs by addressing and curbing the diversion of prescription drugs from legitimate commercial channels. The act imposes stringent regulations on the distribution and sale of prescription medications, aiming to protect consumers from counterfeit, adulterated, misbranded, subpotent, and expired drugs.

Background

Prior to the enactment of the PDMA, the pharmaceutical industry faced challenges related to the distribution of prescription drugs that compromised patient safety. The secondary market for pharmaceuticals, which often involved the sale of drugs outside of the manufacturer's authorized distribution channels, was particularly problematic. This market was prone to infiltration by counterfeit and substandard products. In response to these concerns, Congress passed the PDMA to tighten control over the drug distribution system and enhance the integrity of the pharmaceutical supply chain.

Key Provisions

The PDMA introduced several key provisions aimed at regulating the distribution of prescription drugs:

• Prohibition of Re-importation: The act generally prohibits the re-importation of prescription drugs into the United States by anyone other than the manufacturer. This measure was intended to prevent the circulation of potentially unsafe drugs that might enter the U.S. market through unregulated channels.

• Restrictions on Distribution: The PDMA restricts the distribution of prescription drugs to licensed practitioners and authorized distributors. This provision seeks to ensure that drugs are dispensed and sold only by entities that meet federal standards for handling prescription medications.

• Sample Distribution Controls: The act sets forth specific requirements for the distribution of free samples of prescription drugs by manufacturers and representatives. These controls are designed to prevent the misuse of samples and ensure they are used for legitimate medical purposes.

• Licensing of Wholesalers: The PDMA mandates state licensing of drug wholesalers, requiring them to adhere to federal standards. This provision aims to enhance the oversight of drug distribution and reduce the risk of counterfeit drugs entering the supply chain.

• Recordkeeping and Reporting: The act requires detailed recordkeeping and reporting by manufacturers and distributors of prescription drugs. These requirements facilitate the tracking of drug distribution and help in identifying and addressing any irregularities.

Impact

The implementation of the PDMA has had a profound impact on the pharmaceutical industry and the safety of prescription drugs. By establishing a more secure and transparent drug distribution system, the act has contributed to a reduction in the incidence of drug diversion and the circulation of counterfeit drugs. It has also reinforced the importance of compliance with federal regulations among manufacturers, distributors, and other stakeholders in the pharmaceutical supply chain.

Challenges and Criticisms

Despite its successes, the PDMA has faced challenges and criticisms. Some stakeholders have argued that the act imposes burdensome regulatory requirements that can increase operational costs and reduce efficiency. There have also been concerns about the act's impact on access to prescription drugs, particularly in situations where restrictions on drug distribution might limit the availability of medications to patients in need.

Conclusion

The Prescription Drug Marketing Act of 1987 represents a critical effort to safeguard the pharmaceutical supply chain in the United States. By addressing the risks associated with drug diversion and the distribution of counterfeit and substandard products, the PDMA has played a key role in protecting public health. Ongoing efforts to enforce and refine the provisions of the act continue to be essential in ensuring the safety and integrity of prescription drugs.